https://ayeshaaiman.netlify.app/project/ProjectsWowchemy (https://wowchemy.com)en-usSun, 28 Aug 2022 00:00:00 +0000https://ayeshaaiman.netlify.app/media/icon_hu526bd703046e832ca61acfebb737825a_5312_512x512_fill_lanczos_center_3.pnghttps://ayeshaaiman.netlify.app/project/https://ayeshaaiman.netlify.app/project/1.research_interests/Sat, 27 Aug 2022 00:00:00 +0000https://ayeshaaiman.netlify.app/project/1.research_interests/<!-- Multiple sclerosis (MS) is a metabolically dependent neurodegenerative disorder caused by persistent axonal loss of the brain and spinal cord. It is the most prevalent cause of non-traumatic neurological disability among young adults, especially females, in Western countries. DMTs and cost-effective pharmacotherapies can help patients address their condition by lowering their risk of relapse, postponing disability, and/or having fewer Magnetic resonance imaging (MRI) lesion loads. Interferon is one of the first-line therapies to treat MS patients in India. This project addresses the desire for developing novel therapeutic regimens and their essential role in improving patients’ health. -->https://ayeshaaiman.netlify.app/project/2.phd_research/Sun, 28 Aug 2022 00:00:00 +0000https://ayeshaaiman.netlify.app/project/2.phd_research/<p>Multiple sclerosis (MS) is a metabolically dependent neurodegenerative disorder caused by persistent axonal loss of the brain and spinal cord. It is the most prevalent cause of non-traumatic neurological disability among young adults, especially females, in Western countries. DMTs and cost-effective pharmacotherapies can help patients address their condition by lowering their risk of relapse, postponing disability, and/or having fewer brain lesion loads. Interferon is one of the first-line therapies to treat MS patients in India. This project addresses the desire for developing novel therapeutic regimens and their essential role in improving patients’ health.</p>